Inje University Industry-Academic Cooperation Foundation

Eyebio Korea

Ti Inc.

Future Medicine Co., Ltd.

Jae Wook Yang

Hye Sook Lee

Sung Hyuk Moon

Ji Hyun Lee

Chae Eun Kim

Yoon Jin Lee

Dae Jin Kim

Moon Sue Lee

Hyuk Woo Lee

Seung Jai Lee

Hae Shin Lee

Mi Ra Yu

Ga Bin Park

Bo Mi Park

Hyun Kyung Lee

Yeong Seok Kim

Chong-Woo Park

Dae Young Hur

Jee Young Kim

Ji Youn Lee

Whui Su Shim

Kun Moo Lee

Seong Han Kim

Hong Jai Lee

Hyun Jeong Kang

Sun Joon Hwang

The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease

A capsulorhexis device is inserted into an incision site of a cornea to make an incision in an anterior capsule surrounding a crystalline lens. The capsulorhexis device includes a loop having elasticity and conductivity; a moving member having one end fixed and coupled to the loop; an insertion guide configured so that, while the incision is being made in the crystalline lens capsule, a front end thereof is inserted into the incision site of the cornea; and a housing having one end coupled to a rear end of the insertion guide, wherein the loop is housed in the housing and, to make the incision in the crystalline lens capsule, slides in the housing together with the moving member to pass through the insertion guide and be deployed into an anterior chamber of the eye.

Capsulotomy device

Provided is a capsulorhexis apparatus for incising an anterior capsule covering a crystalline lens by being inserted into an incision site of a cornea, the capsulorhexis apparatus including: an anterior capsule incision portion which has a closed curve shape, is inserted into the incision site of the cornea to incise the anterior capsule located below the cornea to a circle, and generates heat by using high frequency vibration to incise the anterior capsule; a body portion which is externally exposed when the anterior capsule incision portion incises the anterior capsule while slidingly moving in the body portion, and is internally inserted when the anterior capsule incision portion does not incise the anterior capsule; and a button portion which is formed on one side of the body portion and slidingly moves the anterior capsule incision portion inside the body portion.

Capsulorhexis apparatus

A composition for preventing or treating dry eye syndrome includes nanocomposite of a polyethylene glycol and a flavonoid as an active ingredient, and in the present invention, a catechin/PEG nanocomposite having increased catechin bioavailability is prepared by using catechins which are an antioxidant and polyethylene glycol which is a hydrophilic polymer used in a drug delivery system, and an increase in tear generation, stabilization of corneal epithelial cells, an increase in conjunctival goblet cells and enhanced anti-inflammatory effects accordance to a PEG dosage by the catechin/PEG nanocomposite are confirmed in a mouse model with dry eye syndrome.

Composition, for preventing or treating dry eye syndrome, containing polyethylene glycol and flavonoid nanocomposite as active ingredient

The present invention relates to a pharmaceutical composition for preventing or treating dry eye, the pharmaceutical composition including, as an active component, a novel peptide is disclosed, wherein it is confirmed that the peptide has effects on improving tear production and corneal surface smoothness for dry eyes induced by desiccation stress and suppressing detachment of corneal epithelial cells, reduction in conjunctival goblet cells, and generation of inflammatory factors, thereby applying a composition including the peptide as an active component to the pharmaceutical composition for preventing or treating dry eye.

Pharmaceutical composition for preventing or treating dry eyes

Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II &#x3b1;1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.

Chondrocyte extracellular matrix-derived peptide

The present invention relates to a cell model for diseases associated with corneal neovascularization by using Epstein Barr virus (EBV)-infected human corneal epithelial cells (HCECs). Provided are a method for preparing a cell model for diseases associated with corneal neovascularization by using EBV-infected HCECs, the method including: infecting HCECs with EBV; culturing the infected HCECs; and determining whether the cultured HCECs are infected with EBV. In addition, provided is a method for screening diseases associated with corneal neovascularization prepared by the cell model for diseases associated with corneal neovascularization.

Cell model for neovascular diseases using EBV-infected human corneal epithelial cells

A pharmaceutical composition for preventing or treating an ocular surface disease is disclosed, wherein the pharmaceutical composition includes, as an active component, collagen type II &#x3b1;1 based peptide SEQ ID NO: 2 isolated from chondrocyte-derived extracellular matrix (CDEM). In an alkaline burn animal mode treated with peptide SEQ ID NO: 2, the occurrence of corneal opacification is reduced as well as the expression of angiogenic factors. In addition, the expression of inflammatory markers is reduced while the expression of inflammation-inducing factor is suppressed. The peptide SEQ ID NO: 2 may be applied to a pharmaceutical composition for preventing or treating an ocular surface disease.

Pharmaceutical composition for preventing or treating ocular surface disease

Provided is a pterygium animal model produced by injecting human-derived pterygial epithelial cells that are isolated and cultured in vitro. The animal model has characteristics similar to those of pterygium, which are observed only in humans, wherein such characteristics are caused in such a way that pterygial epithelial cells are isolated from human pterygium corneal tissues and cultured, the cultured pterygial epithelial cells are sub-cultured, and human-derived pterygial epithelial cells of which identify is confirmed are injected into the nasal subconjunctival space of mice. The pterygium animal model allows a pterygium therapeutic agent to be effectively screened.

Pterygium animal model using human pterygial epithelial cells

Growing community of inventors

Busan, South Korea

Jae Wook Yang